FTC Permitted To Force Exec Testimony In AndroGel Trial
When the Federal Trade Commission goes to trial next month with allegations that AbbVie Products LLC and Actavis Inc. conspired to delay generic versions of the testosterone drug AndroGel, it will...To view the full article, register now.
Already a subscriber? Click here to view full article